Oppenheimer & Co, a leading full-service brokerage and investment bank, released its top equity ideas list on November 16.
“These are the most timely stocks in the opinion of our research analysts,” the report explained.
Each of Oppenheimer’s 33 equity analysts picked an individual stock they believe will outperform over the next 12 months based on fundamentals and market conditions.
This week, investors have been returning to value and recovery stocks as the vaccine frontrunners, Pfizer, Moderna and AstraZeneca, announced promising updates. This has led to a rotation out of growth stocks, many of which were stay-at-home winners, into value stocks, which have been worst-hit by the pandemic.
Investors continue to move into risk assets, such as equities, in search of income as bond yields remain low. Many top investment banks have been advising investors to consider alternative assets when looking for income and diversification.
However, the continual rise of COVID-19 cases combined with stricter lockdowns across many states in the United States and in Europe continues to weigh on investors’ minds. This is especially true because a second stimulus package in the United States is yet to be passed. This has created swings in the markets as investors alternate between optimism and caution.
The list takes into consideration this current volatile market environment to provide the best equity picks going into 2021.
The analysts in the report note that the list is a menu for investors to choose from, rather than a portfolio.
Here is the full list:
Equity analysts from leading investment bank, Oppenheimer & Co, each picked an individual stock expected to outperform in the next 12 months.
